PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) expects interim clinical data from two experimental cancer therapies later this year as the biotechnology company advances multiple bispecific antibody programs targeting solid tumors.
The company expects Phase 1a interim data for CTIM-76, a CLDN6 x CD3 bispecific antibody candidate, in June 2026, followed by Phase 1a data for CT-95, a mesothelin-targeting therapy, in September.
Context also plans to begin a Phase 1 clinical trial in the third quarter for CT-202, a Nectin-4 x CD3 bispecific antibody candidate, after receiving regulatory clearance in Australia in April.
Chief Executive Officer Martin Lehr said the company remains on schedule across its clinical pipeline and expects the upcoming CTIM-76 data release to include preliminary safety and efficacy findings.
In April, the U.S. Food and Drug Administration granted Fast Track designation to CTIM-76 for platinum-resistant ovarian cancer in patients who have exhausted standard treatment options.
The company also presented preclinical data for CT-202 at the American Association for Cancer Research Annual Meeting in April.
Context reported cash and cash equivalents of $54.5 million as of March 31, compared with $66 million at the end of 2025. The company expects existing cash reserves to fund operations into mid-2027.
Research and development expenses increased to $7 million in the first quarter from $3.5 million a year earlier, driven primarily by higher spending on the CTIM-76, CT-202 and CT-95 programs, along with increased personnel costs.
General and administrative expenses rose modestly to $2.3 million from $2.1 million in the prior-year quarter.
Net loss widened to $8.7 million in the first quarter ended March 31, compared with $4.6 million during the same period last year.
Other income declined to $0.7 million from $1 million, primarily reflecting lower interest income on cash balances.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.